NGENLA
Drug
PFIZER INC.
Total Payments
$428,535
Transactions
200
Doctors
85
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $245,202 | 118 | 70 |
| 2023 | $183,333 | 82 | 35 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $245,654 | 15 | 57.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $86,894 | 40 | 20.3% |
| Consulting Fee | $82,137 | 24 | 19.2% |
| Travel and Lodging | $10,153 | 19 | 2.4% |
| Food and Beverage | $3,658 | 101 | 0.9% |
| Education | $38.60 | 1 | 0.0% |
Payments by Type
Research
$245,654
15 transactions
General
$182,881
185 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| COLLAGEN X BIOMARKER AS A PREDICTOR OF RESPONSE TO GROWTH HORMONE THERAPY | PFIZER INC. | $135,000 | 0 |
| A RANDOMIZED CLINICAL TRIAL OF TWO DIFFERENT INITIAL GROWTH HORMONE DOSES IN CHILDREN WITH GROWTH HORMONE DEFICIENCY IN THE FIRST YEAR OF TREATMENT | PFIZER INC. | $99,999 | 0 |
| NGENLA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $8,480 | 4 |
| A MULTICENTER LOWINTERVENTIONAL STUDY TO EVALUZTE AND MONITOR TREATMENT EXPERENCE WITHH WEEKLY GROWTH HORMONENGENLA VERSUS DAILY GROWTH HORMONE INJECTIONS IN CHILDREN WITH GROWTH HORMONE DEFICIENCY | PFIZER INC. | $2,175 | 0 |
Top Doctors Receiving Payments for NGENLA — Page 4
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , CPNP-PC | Pediatrics | El Paso, TX | $15.21 | 1 |
| , MD | Pediatric Endocrinology | Leawood, KS | $14.77 | 1 |
| , CPNP-PC | Pediatrics | Des Moines, IA | $14.40 | 1 |
| , MD | Pediatric Endocrinology | Des Moines, IA | $14.40 | 1 |
| , MD | Pediatric Endocrinology | Des Moines, IA | $14.40 | 1 |
| , M.D | Pediatric Endocrinology | Des Moines, IA | $14.40 | 1 |
| , MD | Pediatric Endocrinology | Des Moines, IA | $14.40 | 1 |
| , M.B.B.S | Pediatric Endocrinology | Des Moines, IA | $14.40 | 1 |
| , DNP | Pediatric Endocrinology | Des Moines, IA | $14.40 | 1 |
| , MD | Pediatric Endocrinology | Topeka, KS | $13.66 | 1 |
| , D.O | Endocrinology, Diabetes & Metabolism | Plano, TX | $13.20 | 1 |
Ad
Manufacturing Companies
- PFIZER INC. $428,535
Product Information
- Type Drug
- Total Payments $428,535
- Total Doctors 85
- Transactions 200
About NGENLA
NGENLA is a drug associated with $428,535 in payments to 85 healthcare providers, recorded across 200 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2023 to 2024. In 2024, $245,202 was paid across 118 transactions to 70 doctors.
The most common payment nature for NGENLA is "Unspecified" ($245,654, 57.3% of total).
NGENLA is associated with 4 research studies, including "COLLAGEN X BIOMARKER AS A PREDICTOR OF RESPONSE TO GROWTH HORMONE THERAPY" ($135,000).